At the annual Nordic Life Science Days, Elypta was announced the winner of the Nordic Life Science Award as well as the Delegates’ Choice Award, the latter voted for by the delegates at the conference. Elypta was awarded for their achievement in combining distinguished science and technology to create a disruptive platform for the early detection of cancer.
Elypta has initiated preparations for the AURORAX-087 study to generate evidence to support regulatory approval for the first application, monitoring of recurrence in renal cell carcinoma patients. The study is the largest so far centered around kidney cancer diagnostics. Factory-CRO, a CRO specialised in clinical trial management in medtech and IVD was recently selected for the managment of the study.
First Word Medtech covered the announcement here:
Elypta is a finalist in this year’s Medtech Insight Awards, an award that celebrates and recognizes excellence among the companies, teams, and individuals driving positive change across the global medtech industry.
Elypta is nominated for Best Technological Innovation: Diagnostics.
“We are delighted with this nomination,” says Karl Bergman, CEO of Elypta. “Accurate, rapid and cost-effective diagnostics are essential to fulfill the promise of precision medicine and we believe we need to find markers also in metabolism to achieve this. We are already gaining a great deal of interest in the US for our approach and this nomination will help raise our profile further.”
Elypta participated in the Serendipity Challenge finals at Techarenan in Almedalen, Visby - a focal point for Swedish industry and policymakers at an annual gathering in July every year. Elypta was one of 50 selected start-ups among over 400 applicants.
Following initial pitches to a jury of investors and subsequent presentations by the top 7 companies to the audience at Techarenan, Elypta was awarded Nordic Start-up of the year for its rapid progress towards introducing novel biomarkers for early detection of cancer. The competition is in its 5th year and attracts start-ups from across sectors, focusing on Tech.
The award is a great recognition for the efforts of the team over the last year.
Elypta had the great pleasure to host Dr. Robert Langer, Institute Professor at MIT and long time advisor for our company, and his son Sam. We are grateful also for the US Embassy’s assistance in accomodating the visit.
Elypta participated in the Swedish American Life Science Summit in Washington DC on April 10. CEO Karl Bergman participated in a round-table discussion on precision medicine in oncology led by the President of Biden Cancer Initiative, Greg Simon.
Elypta was selected as one of twelve start-ups across Europe to present at BIO Europe Spring Start-up Spotlight event. Karl Bergman will be in Vienna for the event on March 26th.
The Horizon 2020 award announcement has led to increased interest in Elypta’s activities. 360Dx interviewed Karl Bergman (CEO) and Saeed Dabestani, Urologic surgeoun at Skåne University Hospital, senior associate at the European Association of Urology, Guidelines panel for RCC and medical advisor to Elypta on the application of the technology in RCC. Full article here.
Elypta today announced it is one of the winners in the European Union’s Horizon 2020 Research and Innovation Programme SME instrument phase 2 and has been awarded Euros 2.35 m. The grant will fund the first ever multicenter trial for diagnoses of renal cell carcinoma (RCC), aimed at validating the company's innovative metabolism-based liquid biopsy platform for early detection of recurrent RCC and thus enabling the test to be launched in Europe and the US.
Select press coverage:
Elypta’s CSO Francesco Gatto was today included in the European edition of MIT Technology Review’s annual 35 Innovators Under 35 for the ground breaking research he leads at Elypta.
We are delighted to announce that Elypta yet again qualified as a global top 500 DeepTech start-up in the annual competition held by Hello Tomorrow. We will attend the finals at the Global Summit in 2019.
As of January, Anders Ekblom has joined the team. Anders brings a wealth of experience from the life science and healthcare industries and is a great addition to Elypta's board of directors.
We are delighted to announce that Elypta has been chosen by Hello Tomorrow Nonprofit as one of the world’s TOP 500 deep-tech startups! Elypta is one of 50 companies progressing in the Healthcare track. Come meet us at the HTSummit in Paris this October.